Renaissance of 6-Diazo-5-oxo-ʟ-norleucine (DON): Prodrug Strategy as a Promising Tool Leading to Potential Anticancer Drug

The natural compound 6-diazo-5-oxo-ʟ-norleucine (DON) has shown promising anticancer activity in several preclinical and early clinical studies, but its further development has been hampered by adverse toxicity, mainly in the gastrointestinal tract. This review discusses the renaissance of DON throu...

Full description

Saved in:
Bibliographic Details
Published inChemické listy Vol. 119; no. 5; pp. 274 - 286
Main Author Tenora, Lukáš
Format Journal Article
LanguageCzech
English
Published 15.05.2025
Online AccessGet full text
ISSN0009-2770
1213-7103
1803-2389
1213-7103
DOI10.54779/chl20250274

Cover

Abstract The natural compound 6-diazo-5-oxo-ʟ-norleucine (DON) has shown promising anticancer activity in several preclinical and early clinical studies, but its further development has been hampered by adverse toxicity, mainly in the gastrointestinal tract. This review discusses the renaissance of DON through prodrug strategies. Using rational strategies, we have developed hundreds of tumor- and brain-targeted prodrugs with improved pharmaco­kinetic and pharmacodynamic properties and without severe toxicity. The most promising prodrug, sirpiglenastat, entered clinical trials in 2020 under the leadership of Dracen Pharmaceuticals and is currently being tested in combination with durvalumab in patients with fibrolamellar hepatocellular carcinoma.
AbstractList The natural compound 6-diazo-5-oxo-ʟ-norleucine (DON) has shown promising anticancer activity in several preclinical and early clinical studies, but its further development has been hampered by adverse toxicity, mainly in the gastrointestinal tract. This review discusses the renaissance of DON through prodrug strategies. Using rational strategies, we have developed hundreds of tumor- and brain-targeted prodrugs with improved pharmaco­kinetic and pharmacodynamic properties and without severe toxicity. The most promising prodrug, sirpiglenastat, entered clinical trials in 2020 under the leadership of Dracen Pharmaceuticals and is currently being tested in combination with durvalumab in patients with fibrolamellar hepatocellular carcinoma.
Author Tenora, Lukáš
Author_xml – sequence: 1
  givenname: Lukáš
  orcidid: 0000-0002-6982-3545
  surname: Tenora
  fullname: Tenora, Lukáš
BookMark eNp9kMtKAzEUhoNUsK3ufIAsFYyeZK5xVzreoNiidT1kJkmNTJOSTNHqw_g-PpVT68KVq59z-PgP5xugnnVWIXRM4TyJs4xf1M8NA5YAy-I91KeMRiSjEPVQHwA4YVkGB2gQwgtATClnffTxoKwwIQhbK-w0TklhxLsjCXFvjnx9Eut8o9a1sQqfFNP700s880769QI_tl60arHBImCx3S5NMHaB5841eKKE3A6twzPXKtsa0eBRF_X2ksdF13CI9rVogjr6zSF6ur6aj2_JZHpzNx5NSE1TaEmVRzmtqgpYpDNJgbM45UpyrUGriElG8-4ZllCW5qA1T2OpJVUgeachljQaIrLrXduV2LyKpilX3iyF35QUyh9z5R9zHX-242vvQvBK_49_A7IkcWI
ContentType Journal Article
DBID AAYXX
CITATION
ADTOC
UNPAY
DOI 10.54779/chl20250274
DatabaseName CrossRef
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
Database_xml – sequence: 1
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1213-7103
EndPage 286
ExternalDocumentID 10.54779/chl20250274
10_54779_chl20250274
GroupedDBID -~X
2WC
6J9
77Q
AAYXX
ACGFO
AENEX
ALMA_UNASSIGNED_HOLDINGS
CITATION
DU5
EBS
EJD
HH5
OK1
OVT
P2P
RNS
XSB
~02
53G
ADTOC
AI.
C1A
UNPAY
VH1
ID FETCH-LOGICAL-c160t-b8381bbb023f7d1092469ed9ff0fe32d2184112512680ff964dfd1e0d92744d13
IEDL.DBID UNPAY
ISSN 0009-2770
1213-7103
1803-2389
IngestDate Wed Oct 01 15:20:09 EDT 2025
Wed Oct 01 06:02:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language Czech
English
License cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c160t-b8381bbb023f7d1092469ed9ff0fe32d2184112512680ff964dfd1e0d92744d13
ORCID 0000-0002-6982-3545
OpenAccessLink https://proxy.k.utb.cz/login?url=http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/download/5003/4970
PageCount 13
ParticipantIDs unpaywall_primary_10_54779_chl20250274
crossref_primary_10_54779_chl20250274
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-05-15
PublicationDateYYYYMMDD 2025-05-15
PublicationDate_xml – month: 05
  year: 2025
  text: 2025-05-15
  day: 15
PublicationDecade 2020
PublicationTitle Chemické listy
PublicationYear 2025
SSID ssj0041192
ssib001785779
ssib006287646
Score 2.3502462
Snippet The natural compound 6-diazo-5-oxo-ʟ-norleucine (DON) has shown promising anticancer activity in several preclinical and early clinical studies, but its...
SourceID unpaywall
crossref
SourceType Open Access Repository
Index Database
StartPage 274
Title Renaissance of 6-Diazo-5-oxo-ʟ-norleucine (DON): Prodrug Strategy as a Promising Tool Leading to Potential Anticancer Drug
URI http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/download/5003/4970
UnpaywallVersion publishedVersion
Volume 119
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFSB
  databaseName: Free Full-Text Journals in Chemistry
  customDbUrl:
  eissn: 1213-7103
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0041192
  issn: 0009-2770
  databaseCode: HH5
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://abc-chemistry.org/
  providerName: ABC ChemistRy
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaq7aFcKAUqSqHyARAc3MR5ODG3qktVIVhWqCu1p5Ud2wgaxdU2adnyY_g__KrO5IFaVao4cIuikR-ZUWbG_uYbQl6pBIJ2aQ0Li1wwiG85UzkkK-DJpItiETqLBc6fJ-Jwlnw8To9XyFB7gqjKoq2UP7WshI0ud4urwP84j4OWPRApI4LbAkH_iQOD7PJemSDFw7lEZpDJrwq8dxqR1dlkuncydFWLsraJHLKZIRaxBeHnYczAfckOHJ8mWSZhojLCGCHKkltua62pztTyUpXlDV90sE4uhoqeDoJyutvUGtd_h-Dx_27zEXnYR690rxPaICu2ekzW9oemcU_Ir6-2UqBLtCXqHRVs_F1deZYy_9OzP79Z5RelbfA2n74df5m8e0-n8AtfNN9oz5O7pOqcKnwLY4JfpUfel_RTh_WntadTXyPCCZdR4UE8zLSgYxjhKZkdfDjaP2R9fwdWcBHWTOcQLmitIWxwmeEhpIICzEY6BxYSRwazT94GYCIPnZMiMc5wGxqJtIaGx5tkVPnKPiMUfHGW6igXCvnSdKZVYbgQOi9ibqXWW-T1oL75WUfjMYf0p1Xz_Iaat8ibv7q9V_D5vwpukwf4iIADnr4go3rR2JcQx9R6B71IutPb5jWEbvHl
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaq7aFcKBQQfYB8KAgObuI8nJhb1aWqqrKsUFcqp5Ud2xU0iqtt0rLlx_B_-FXM5IFaISEO3KJo5EdmlJmxv_mGkF2VQNAurWFhkQsG8S1nKodkBTyZdFEsQmexwPnDRBzNkuOz9GyFDLUniKos2kr5C8tK2Ohyr7gN_NerOGjZA5EyIrgvEPSfODDILu-VCVI8nEtkBpn8qsB7pxFZnU2m-5-HrmpR1jaRQzYzxCK2IPw8jBm4L9mB49MkyyRMVEYYI0RZcs9trTXVpVreqLK844sO18n1UNHTQVAu9ppa4_r_IHj8v9t8RB720Svd74QekxVbbZC1g6Fp3BPy_ZOtFOgSbYl6RwUbf1G3nqXMf_Ps5w9W-UVpG7zNp2_GHydv39Ep_MIXzTnteXKXVF1RhW9hTPCr9NT7kp50WH9aezr1NSKccBkVHsTDTAs6hhGektnh-9ODI9b3d2AFF2HNdA7hgtYawgaXGR5CKijAbKRzYCFxZDD75G0AJvLQOSkS4wy3oZFIa2h4_IyMKl_Z54SCL85SHeVCIV-azrQqDBdC50XMrdR6k7wa1De_7Gg85pD-tGqe31HzJnn9W7d_Fdz6V8Ft8gAfEXDA0x0yqheNfQFxTK1f9lb5C96t8P8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renaissance+of+6-Diazo-5-oxo-%CA%9F-norleucine+%28DON%29%3A+Prodrug+Strategy+as+a+Promising+Tool+Leading+to+Potential+Anticancer+Drug&rft.jtitle=Chemick%C3%A9+listy&rft.au=Tenora%2C+Luk%C3%A1%C5%A1&rft.date=2025-05-15&rft.issn=0009-2770&rft.eissn=1213-7103&rft.volume=119&rft.issue=5&rft.spage=274&rft.epage=286&rft_id=info:doi/10.54779%2Fchl20250274&rft.externalDBID=n%2Fa&rft.externalDocID=10_54779_chl20250274
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-2770&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-2770&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-2770&client=summon